Want to see VKTX full AI Analyst Report?
VKTX Stock Chart & Stats
$34.17
-$0.60(-1.70%)
At close: 4:00 PM EDT
$34.17
-$0.60(-1.70%)
Day’s Range― - ―
52-Week Range$24.94 - $43.15
Previous CloseN/A
Volume1.84M
Average Volume (3M)7.36M
Market Cap
$3.40B
Enterprise Value$4.04B
Total Cash (Recent Filing)$501.66M
Total Debt (Recent Filing)$4.09M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Oct 28, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding127,165,250
10 Day Avg. Volume5,952,643
30 Day Avg. Volume7,362,553
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.41K
Enterprise Value/Ebitda-7.56
Forecast
1Y Price Target
$91.71Price Target Upside168.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-4.6
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising VK2735 Maintenance ProfileThe maintenance results suggest VK2735 may preserve substantial weight loss with less frequent dosing, potentially improving convenience and adherence. Flexible schedules could strengthen the product’s future commercial positioning and differentiate it in a competitive obesity-treatment market.
Large Phase III Obesity Program Fully EnrolledCompletion of enrollment in two large Phase III studies reduces a major execution hurdle and advances VK2735 toward pivotal efficacy and safety readouts. The scale of the program can support a more robust regulatory package if the trials confirm earlier clinical findings.
Expanded Funding Supports Long-term DevelopmentNew equity and convertible financing materially increases resources available for late-stage VK2735 development, VK3019 advancement, and potential commercialization preparation. Combined with management’s stated runway into 2028, the capital supports continued execution without relying immediately on partnership revenue.
Bears Say
Pre-revenue Model With Rapidly Widening LossesThe absence of product revenue means Viking must fund a growing operating base before any commercial return is established. Rapidly expanding losses increase dependence on external capital and leave future earnings highly contingent on successful clinical development and regulatory approval.
Accelerating Cash Burn Raises Funding PressureIncreasing cash outflows show that advancing multiple late-stage programs requires substantially more funding over time. Even with recent financing and a stated runway into 2028, sustained burn can constrain strategic flexibility and create recurring dilution or financing needs before commercialization.
Clinical And Maintenance-readout Uncertainty Remains MaterialThe maintenance findings may not fully establish long-term tolerability or durability because the study window is short and titration differs from VANQUISH. Separately, VK3019 is still early stage, so important pipeline value remains dependent on future human data and later-stage execution.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $24.94 and its highest was $43.15 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.40B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 6 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Jul 29, 2026. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.233 by $0.133.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 127,165,250 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.233. Following the earnings report the stock price went down -0.957%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.71 (168.38% Upside)
$91.71 (168.38% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 85%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 3.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.85%
12-Months-Change
Fundamentals
Return on Equity
-94.56%
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
VKTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights substantial clinical progress: fully enrolled large Phase III programs for subcutaneous VK2735, positive Phase II efficacy for both subcutaneous and oral formulations (notably up to 14.7% and 12.2% mean weight loss, respectively), initiation of an early-stage amylin/calcitonin program (VK3019), and organizational hires to support commercialization. These scientific and pipeline milestones are balanced against materially higher R&D spend, widening net losses and a meaningful cash decline (~28.9% year-to-date). Management reiterated cash runway into 2028 and expects cash burn to taper, while noting upcoming maintenance study data and oral Phase III initiation later in the year. Overall, clinical momentum and promising efficacy data are dominant positives, while financial burn and early-stage uncertainties are notable negatives.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$91.71
▲(168.38% Upside)
Technical Analysis
NewAmsterdam Pharma Company
―
Mineralys Therapeutics, Inc.
―
Structure Therapeutics, Inc. Sponsored ADR
―
Kailera Therapeutics, Inc.
―
Parabilis Medicines, Inc.
―
Ownership Overview
2.72% Insiders
16.72% Mutual Funds
0.60% Other Institutional Investors
66.47% Public Companies and Individual Investors